Skip to content

Cystic Fibrosis Canada Deadline Of October 10, 2012 For Patient Input On Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor)

October 4, 2012

       Cystic Fibrosis (CF) Canada issues an important update: Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) patient input submissions are due by Wednesday, October 10, 2012. Per the update :

–    Kalydeco is going through the Common Drug Review (CDR) in Canada

–    Approximately 100 patients with G551D mutation in Canada

–    Making contact with these patients through the clinics

–    Patient Contribution Form attached to this notice.

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: